Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 10 684 / https://doi.org/10.3332/ecancer.2016.684

Special Issue

Next-generation sequencing in NSCLC and melanoma patients: a cost and budget impact analysis

Next-generation sequencing (NGS) has reached the molecular diagnostic laboratories. Although the NGS technology aims to improve the effectiveness of therapies by selecting the most promising therapy, concerns are that NGS testing is expensive and that the ‘benefits’ are not yet in relation to these costs. In this study, we give an estimation of the costs and an institutional and national budget impact of various types of NGS tests in non-small-cell lung cancer (NSCLC) and melanoma patients within the Netherlands. First, an activity-based costing (ABC) analysis has been conducted on the costs of two examples of NGS panels (small- and medium-targeted gene panel (TGP)) based on data of the Netherlands Cancer Institute (NKI). Second, we performed a budget impact analysis (BIA) to estimate the current (2015) and future (2020) budget impact of NGS on molecular diagnostics for NSCLC and melanoma patients in the Netherlands. Literature, expert opinions, and a data set of patients within the NKI (n = 172) have been included in the BIA. Based on our analysis, we expect that the NGS cost concerns will be limited. In the current situation, NGS can indeed result in higher costs, which is mainly related to required additional tests besides the small TGP. However, in the future, we expect that the use of whole-genome sequencing (WGS) will increase, for which it is expected that additional tests can by (partly) avoided. Although the current clinical benefits are expected to be limited, the research potentials of NGS are already an important advantage.

Keywords: Next-generation sequencing, test costs, budget impact, melanoma, NSCLC, personalised medicine, targeted therapy

Loading Article Metrics ... Please wait

Related articles

Research: Breast lesions with atypia in percutaneous biopsies, managed with surgery in the last 10 years

Abstract | Full Article | PDF | Spanish Published: 11 Apr 2019 / https://doi.org/10.3332/ecancer.2019.923

Case Report: Primary cardiac angiosarcoma diagnosed in the first trimester of pregnancy

Abstract | Full Article | PDF Published: 09 Apr 2019 / https://doi.org/10.3332/ecancer.2019.922

Clinical Study: Assessing the tolerability and efficacy of first-line chemotherapy in elderly patients with metastatic HER2−ve breast cancer

Abstract | Full Article | PDF Published: 03 Apr 2019 / https://doi.org/10.3332/ecancer.2019.921

Policy: Precision oncology in Latin America: current situation, challenges and perspectives

Abstract | Full Article | PDF | Spanish Published: 03 Apr 2019 / https://doi.org/10.3332/ecancer.2019.920

Research: Experience with concurrent chemoradiotherapy treatment in advanced cervical cancer: results from a hospital in Argentina

Abstract | Full Article | PDF | Spanish Published: 02 Apr 2019 / https://doi.org/10.3332/ecancer.2019.919



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation